CellCept 250 mg capsules clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
BESTOW: A Phase 2, Multicenter, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation
This study is testing a new medicine, Tegoprubart, to see if it can help prevent the body from rejecting a new kidney after a transplant. Researchers will compare it to standard treatments to check how safe and effective it is.
For: Prophylaxis of Renal Allograft RejectionSpain · France · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A 12-Month, Randomized, Controlled, Open-Label, Dose Escalation Study Evaluating Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Anti-CD2 Monoclonal Antibody, TCD601(siplizumab) Compared to Anti-Thymocyte Globulin (rATG), as Induction Therapy in de novo Renal Transplant Recipients
This study looks at a new medicine called TCD601 (siplizumab) for people who have recently had a kidney transplant. It compares TCD601 to a standard treatment to see if it's safe and how well it helps prevent the body from rejecting the new kidney.
For: Renal TransplantationSweden · Spain · Austria - Ongoing, recruitingPhase III and phase IV (Integrated)
Prospective Randomized trial of Everolimus replacing MMF/MP Acid by the RECOVAC consortium to increase VACcine response in kidney transplant patients
This study looks at how well kidney transplant patients respond to COVID-19 and shingles vaccines when their anti-rejection medication is changed. It compares two different drug treatment plans to see which one helps the body make more protective antibodies.
For: kidney transplantation · COVID-19 · Herpes ZosterNetherlands